Increasing evidence
suggests that the chronicity of wounds
is associated
with the presence of bacterial biofilms. Therefore, novel wound care
products are being developed, which can inhibit biofilm formation
and/or treat already formed biofilms. A lack of standardized assays
for the analysis of such novel antibacterial drug delivery systems
enhances the need for appropriate tools and models for their characterization.
Herein, we demonstrate that optimized and biorelevant in vitro and ex vivo wound infection and biofilm models
offer a convenient approach for the testing of novel antibacterial
wound dressings for their antibacterial and antibiofilm properties,
allowing one to obtain qualitative and quantitative results. The in vitro model was developed using an electrospun (ES) thermally
crosslinked gelatin–glucose (GEL-Glu) matrix and an ex vivo wound infection model using pig ear skin. Wound
pathogens were used for colonization and biofilm development on the
GEL-Glu matrix or pig skin with superficial burn wounds. The in vitro model allowed us to obtain more reproducible results
compared with the ex vivo model, whereas the ex vivo model had the advantage that several pathogens preferred
to form a biofilm on pig skin compared with the GEL-Glu matrix. The in vitro model functioned poorly for Staphylococcus
epidermidis biofilm formation, but it worked well
for Escherichia coli and Staphylococcus aureus, which were able to use the
GEL-Glu matrix as a nutrient source and not only as a surface for
biofilm growth. On the other hand, all tested pathogens were equally
able to produce a biofilm on the surface of pig skin. The developed
biofilm models enabled us to compare different ES dressings [pristine
and chloramphenicol-loaded polycaprolactone (PCL) and PCL−poly(ethylene
oxide) (PEO) (PCL/PEO) dressings] and understand their biofilm inhibition
and treatment properties on various pathogens. Furthermore, we show
that biofilms were formed on the wound surface as well as on a wound
dressing, indicating that the demonstrated methods mimic well the in vivo situation. Colony forming unit (CFU) counting and
live biofilm matrix as well as bacterial DNA staining together with
microscopic imaging were performed for biofilm quantification and
visualization, respectively. The results showed that both wound biofilm
models (in vitro and ex vivo) enabled
the evaluation of the desired antibiofilm properties, thus facilitating
the design and development of more effective wound care products and
screening of various formulations and active substances.